Hutchison China Meditech Limited Block listing Interim Review (4748A)
29 December 2017 - 6:00PM
UK Regulatory
TIDMHCM
RNS Number : 4748A
Hutchison China Meditech Limited
29 December 2017
Blocklisting Six Monthly Return
London: Friday, December 29, 2017: Hutchison China MediTech
Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces the following
blocklisting six monthly return:
1. Name of applicant: Hutchison China MediTech
Limited
2. Name of scheme: Hutchison China MediTech
Limited Share Option
Schemes
3. Period of return: From June 29, 2017 to
December 28, 2017
4. Balance under scheme 1,329,927 ordinary shares
from previous return: of US$1 each
5. The amount by which the Nil
block scheme has been
increased, if the scheme
has been increased since
the date of the last
return:
6. Number of securities 24,928 ordinary shares
issued/allotted under of US$1 each
scheme during period:
7. Balance under scheme 1,304,999 ordinary shares
not yet issued/allotted of US$1 each
at end of the period:
8. Number and class of securities 2,560,606 ordinary shares
originally listed and of US$1 each admitted
the date of admission: on June 26, 2007
9. Total number of securities 66,447,037 ordinary
in issue at the end of shares of US$1 each
the period:
Name of contact: Christian Hogg
Address of contact: 21/F., Hutchison House,
10 Harcourt Road, Hong
Kong
Telephone number of contact: +852 2121 8200
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which
researches, develops, manufactures and sells pharmaceuticals and
healthcare products. Its Innovation Platform, Hutchison MediPharma
Limited, focuses on discovering and developing innovative
therapeutics in oncology and autoimmune diseases for the global
market. Its Commercial Platform manufactures, markets and
distributes prescription drugs and consumer health products in
China.
Chi-Med is majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 1). For more information, please
visit: www.chi-med.com.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President, Corporate Finance
& Development +852 2121 8200
U.K. & International Media Enquiries
Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk
U.S. Based Media Enquiries
Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com
Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com
Investor Relations
Matt Beck, The Trout Group +1 (917) 415 1750 (Mobile) mbeck@troutgroup.com
David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile) david.dible@citigatedewerogerson.com
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts +44 (20) 7886 2500
This information is provided by RNS
The company news service from the London Stock Exchange
END
BLRPGGBPPUPMGGR
(END) Dow Jones Newswires
December 29, 2017 02:00 ET (07:00 GMT)
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From Apr 2024 to May 2024
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From May 2023 to May 2024